Circulating Immunes Cells, Cytokines and Brain Radiotherapy (CYRAD)

  • STATUS
    Recruiting
  • End date
    Oct 23, 2025
  • participants needed
    40
  • sponsor
    Centre Francois Baclesse
Updated on 23 April 2022
carcinoma
squamous cell carcinoma
x-rays

Summary

Patients with malignant tumours of the cephalic pole have a poor prognosis, despite a wide range of treatments. prognosis despite a large therapeutic arsenal. Among this arsenal, radiotherapy (RT) is one of the standard treatments for these tumours. However, this treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic However, this treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic tissue and can promote pro-tumour inflammation.

In these circumstances, hadrontherapy, which uses charged heavy particles, such as protons or carbon ions, is the preferred treatment. protons or carbon ions, seems more appropriate for the treatment of these tumours. However, although inflammation plays a major role in tumour development and tumour development and therapeutic response, few studies have evaluated the immune response response after proton therapy (PT) and carbon therapy (CT). The objective of this project is to study the effect of hadrontherapy on resident/circulating inflammation after brain irradiation. brain irradiation. In a first step, the impact of different PT and CT TEL on macrophages (MФ), the most abundant immune cells in malignant solid tumours, will be evaluated in vitro. malignant solid tumours, will be evaluated in vitro. In a second step, the evolution of circulating leukocytes after brain irradiation with X-rays or protons will be studied in vivo in rodents and patients. rodent and patient. In this project, we propose to study for the first time the inflammatory response after hadrontherapy in the context of a cephalic tumour. cephalic tumour. These results will allow a better understanding of the biological response response following PT and CT with the aim of optimising RT and potentially and potentially translate these data to the clinic.

Details
Condition Head and Neck Cancer
Treatment Collection of blood samples
Clinical Study IdentifierNCT05082961
SponsorCentre Francois Baclesse
Last Modified on23 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients > 18 years
Head and neck cancer: (upper aerodigestive tract, cavum, facial sinus, skull base, brain) operated
Surgery for complete tumour resection or with microscopic residue R1
All possible histologies: squamous cell carcinoma, undifferentiated carcinoma of the nasopharyngeal type (UCNT), adenocarcinoma, adenoid cystic carcinoma, chordoma, chondrosarcoma, other tumours
Patients undergoing exclusive postoperative radiotherapy with a minimum total dose of 60 Gy of X-ray photon radiation or equivalent proton radiation
Patient affiliated to a social security scheme
Signature of the informed consent before any specific procedure related to the study

Exclusion Criteria

Macroscopic postoperative tumour residue R2
Previous cancer within 5 years (except treated basal cell skin carcinoma and treated cervical cancer)
Previous radiotherapy (except brachytherapy of the cervix or prostate)
Chemotherapy or other systemic oncological treatment (cetuximab) concomitant with radiotherapy
Long-term immunosuppressive or corticosteroid therapy
Patient deprived of liberty or under guardianship, protected adult
Patient unable to undergo trial monitoring for geographical, social or psychopathological reasons
Pregnant or breastfeeding woman
Emergency situations
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note